Cyclin-dependent kinase pathways as targets for cancer treatmentSHAPIRO, Geoffrey I.Journal of clinical oncology. 2006, Vol 24, Num 11, pp 1770-1783, issn 0732-183X, 14 p.Article

Aurora Kinase Inhibition As an Anticancer StrategyHILTON, John F; SHAPIRO, Geoffrey I.Journal of clinical oncology. 2014, Vol 32, Num 1, pp 57-59, issn 0732-183X, 3 p.Article

AZ703, an lmidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9DONGPO CAI; BYTH, Kate F; SHAPIRO, Geoffrey I et al.Cancer research (Baltimore). 2006, Vol 66, Num 1, pp 435-444, issn 0008-5472, 10 p.Article

Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phasesMATRANGA, Christian B; SHAPIRO, Geoffrey I.Cancer research (Baltimore). 2002, Vol 62, Num 6, pp 1707-1717, issn 0008-5472Article

The Biology and Clinical Development of MEK Inhibitors for CancerLUKE, Jason J; OTT, Patrick A; SHAPIRO, Geoffrey I et al.Drugs (Basel). 2014, Vol 74, Num 18, pp 2111-2128, issn 0012-6667, 18 p.Article

Combined depletion of cell cycle and transcriptional cyclin- dependent kinase activities induces apoptosis in cancer cellsDONGPO CAI; LATHAM, Vaughan M; XINXIN ZHANG et al.Cancer research (Baltimore). 2006, Vol 66, Num 18, pp 9270-9280, issn 0008-5472, 11 p.Article

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolSHAPIRO, Geoffrey I.Clinical cancer research. 2004, Vol 10, Num 12, pp 4270s-4275s, issn 1078-0432, 2Conference Paper

Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center ExperienceDAHLBERG, Suzanne E; SHAPIRO, Geoffrey I; CLARK, Jeffrey W et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 7, issn 0027-8874, dju163.1-dju163.6Article

Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout miceLECHPAMMER, Mirna; XIANGJUN XU; ELLIS, F. Henry et al.Oncogene (Basingstoke). 2005, Vol 24, Num 10, pp 1683-1688, issn 0950-9232, 6 p.Article

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsSHIMAMURA, Takeshi; LOWELL, April M; ENGELMAN, Jeffrey A et al.Cancer research (Baltimore). 2005, Vol 65, Num 14, pp 6401-6408, issn 0008-5472, 8 p.Article

The aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint functionGIZATULLIN, Farid; YAO YAO; KUNG, Victor et al.Cancer research (Baltimore). 2006, Vol 66, Num 15, pp 7668-7677, issn 0008-5472, 10 p.Article

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumorsSHAPIRO, Geoffrey I; McCALLUM, Stewart; ADAMS, Laurel M et al.Investigational new drugs. 2013, Vol 31, Num 3, pp 742-750, issn 0167-6997, 9 p.Article

Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumorsLORUSSO, Patricia; SHAPIRO, Geoffrey I; HURWITZ, Herbert et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1377-1385, issn 0344-5704, 9 p.Article

The role of metastasis-associated protein 1 in prostate cancer progressionHOFER, Matthias D; KUEFER, Rainer; MENKE, Andre et al.Cancer research (Baltimore). 2004, Vol 64, Num 3, pp 825-829, issn 0008-5472, 5 p.Article

Crizotinib in ROS1-Rearranged Non―Small-Cell Lung CancerSHAW, Alice T; OU, Sai-Hong I; DOEBELE, Robert C et al.The New England journal of medicine. 2014, Vol 371, Num 21, pp 1963-1971, issn 0028-4793, 9 p.Article

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid TumorsSESSA, Cristiana; SHAPIRO, Geoffrey I; QUADT, Cornelia et al.Clinical cancer research (Print). 2013, Vol 19, Num 13, pp 3671-3680, issn 1078-0432, 10 p.Article

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and METLU XU; KIKUCHI, Eiki; SHIMAMURA, Takeshi et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 13, pp 3302-3311, issn 0008-5472, 10 p.Article

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non―Small Cell Lung CancerSHIMAMURA, Takeshi; PERERA, Samanthi A; SINHA, Papiya et al.Clinical cancer research (Print). 2012, Vol 18, Num 18, pp 4973-4985, issn 1078-0432, 13 p.Article

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid TumorsDIAMOND, Jennifer R; BASTOS, Bruno R; MORROW, Mark et al.Clinical cancer research (Print). 2011, Vol 17, Num 4, pp 849-860, issn 1078-0432, 12 p.Article

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to GefitinibENGELMAN, Jeffrey A; ZEJNULLAHU, Kreshnik; ALTHAUS, Irene W et al.Cancer research (Baltimore). 2007, Vol 67, Num 24, pp 11924-11932, issn 0008-5472, 9 p.Article

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome ResistanceZHAO CHEN; AKBAY, Esra; REIBEL, Jacob B et al.Clinical cancer research (Print). 2014, Vol 20, Num 5, pp 1204-1211, issn 1078-0432, 8 p.Article

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and LymphomasHONG, David S; KURZROCK, Razelle; MIER, James et al.Clinical cancer research (Print). 2012, Vol 18, Num 12, pp 3396-3406, issn 1078-0432, 11 p.Article

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignanciesDA ZHANG; MITA, Monica; SHAPIRO, Geoffrey I et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 6, pp 891-898, issn 0344-5704, 8 p.Article

Phase I Studies of CBP501, a G₂ Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid TumorsSHAPIRO, Geoffrey I; TIBES, Raoul; FERNANDEZ, Cristian et al.Clinical cancer research (Print). 2011, Vol 17, Num 10, pp 3431-3442, issn 1078-0432, 12 p.Article

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid TumorsGANDHI, Leena; CAMIDGE, D. Ross; DIVE, Caroline et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 909-916, issn 0732-183X, 8 p.Article